Viruses 2010, 2(8), 1589-1602; doi:10.3390/v2081589

Interferon-λ in HCV Infection and Therapy  

Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
* Author to whom correspondence should be addressed.
Received: 28 June 2010; Accepted: 28 July 2010 / Published: 5 August 2010
(This article belongs to the Special Issue Antivirals Against Hepatitis C Virus)
PDF Full-text Download PDF Full-Text [207 KB, uploaded 5 August 2010 08:57 CEST]
Abstract: Chronic infection with hepatitis C virus (HCV) is associated with significant liver disease and is therefore an important public health problem. The current standard-of-care therapy for chronic HCV infection consists of a combination of pegylated (PEG) interferon (IFN)-α and ribavirin. Although this therapy effectively generates a sustained viral response in approximately half of treated individuals, it is associated with significant hematological and neurological side effects. A new family of IFN-related proteins (IFN-λ1, 2, and 3; or alternately, IL-29, 28A, 28B, respectively) possesses properties that may make these cytokines superior to PEG-IFN-α for HCV therapy. Genetic studies have also implicated these proteins in both the natural and therapy-induced resolution of HCV infection. This review summarizes the basic aspects of IFN-λ biology, the potential role of these cytokines in HCV infection, and the outlook for their therapeutic application.
Keywords: IFN-λ; IL-28; IL-29; type III interferon; IL28B; IL-28Rα

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Pagliaccetti, N.E.; Robek, M.D. Interferon-λ in HCV Infection and Therapy  . Viruses 2010, 2, 1589-1602.

AMA Style

Pagliaccetti NE, Robek MD. Interferon-λ in HCV Infection and Therapy  . Viruses. 2010; 2(8):1589-1602.

Chicago/Turabian Style

Pagliaccetti, Nicole E.; Robek, Michael D. 2010. "Interferon-λ in HCV Infection and Therapy  ." Viruses 2, no. 8: 1589-1602.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert